Serono Phase III Failures Delay Canvaxin BLA, End Onercept Psoriasis Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Serono and CancerVax will continue studying Canvaxin for the treatment of Stage III melanoma following a decision to discontinue a pivotal program in Stage IV disease, the companies said April 6